MNLO - RegeneRx And RGN-137 In Epidermolysis Bullosa: The Story
Introduction
RegeneRx (OTCQB:RGRX) is a small cap ($21M) clinical-stage biopharma developing therapeutics for tissue protection, repair and regeneration. RegeneRx has a diverse clinical pipeline comprising RGN-259, RGN-352 and RGN-137.
The pharmacological target for RGN-137 and other drug assets, RGN-259 and RGN-352, is Thymosin Beta 4 (T?4). Thymosins ?1 and ?4 were initially identified in the thymus, but have since been found to be localised in varied cell types and tissues. Dr. Allan Goldstein, the Chairman of RegeneRx’s Scientific Advisory Board is a pioneer of thymosins biology and clinical potential.
Thymosins